NCT07415252 Herpes zoster vaccine (SK Chemicals) Chickenpox Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Turn a newly registered trial into a decision-ready clinical landscape. This report examines NCT07415252 using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, with Drug & Asset MCP and Company & Deal Intelligence MCP used as the companion asset and sponsor enrichment workflow. Explore PatSnap MCP Servers to reproduce the research sequence inside an AI workflow.
MCP evidence snapshot: 24 August 2026. Trial records, recruitment status and projected dates can change after the snapshot and should be rechecked before operational decisions.
Why NCT07415252 is a hot trial to watch
Chickenpox is being segmented by mechanism, treatment setting, geography and endpoint architecture. NCT07415252 is notable because it evaluates Herpes zoster vaccine (SK Chemicals) in a Phase 3 design sponsored by SK bioscience Co., Ltd.. The main development question is whether the protocol can translate its rationale into a clinically interpretable and operationally credible readout.
Trial landscape snapshot
| Field | Indexed detail |
|---|---|
| Registration | NCT07415252 |
| Official title | SkyVaricella® (NBP608) Vaccine With Lower Potencies in Healthy Children Aged 12 Months to 12 Years |
| Phase / status | Phase 3 / Not yet recruiting |
| Intervention | Herpes zoster vaccine (SK Chemicals) |
| Sponsor | SK bioscience Co., Ltd. |
| Geography | South Korea, Philippines, Honduras, Thailand |
| Enrollment | not reported |
| Primary endpoint | Difference in FAMA Assay-Measured Varicella-Zoster Virus (VZV) Seroconversion Rate 6 Weeks After the First Dose |
| Endpoint time frame | 6 weeks after the first dose. |
| Primary completion / readout proxy | not reported |
Protocol design and endpoint interpretation
The goal of this study is to evaluate the safety and immunogenicity of an investigational varicella vaccine in children. Researchers will compare the investigational vaccine, NBP608, with licensed varicella vaccines. The study includes children aged 12 months to 12 years. Approximately 780 participants will take part in this study. Participants will be randomly assigned to receive either the investigational vaccine (NBP608) or licensed varicella vaccines. Some participants will receive two doses, while others will receive one dose, according to the assigned study group. Participants will: Receive two subcutaneous injections of a study vaccine, administered approximately three months apart (if applicable). Visit the study clinic seven times over approximately 15 months. Receive follow-up phone calls 7 days after each vaccination to monitor for safety.
Allocation is Randomized, masking is Quadruple, and the intervention model is Parallel Assignment. Planned enrollment was not reported; study geography in South Korea, Philippines, Honduras, Thailand shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.
- Difference in FAMA Assay-Measured Varicella-Zoster Virus (VZV) Seroconversion Rate 6 Weeks After the First Dose(6 weeks after the first dose.) — FAMA seroconversion rate will be assessed using the fluorescent antibody to membrane antigen (FAMA) assay to measure varicella-zoster virus (VZV) IgG antibodies and will be compared between the investigational vaccine (NBP608) and a licensed varicella vaccine (Varivax®) 6 weeks after the first dose. The FAMA seroconversion rate is defined as the proportion of participants who are seronegative at baseline (antibody ti
- Difference in FAMA Assay-Measured Varicella-Zoster Virus (VZV) Seroconversion Rate 6 Weeks After the Second Dose(6 weeks after the second dose.) — FAMA seroconversion rate will be assessed using the fluorescent antibody to membrane antigen (FAMA) assay to measure varicella-zoster virus (VZV) IgG antibodies and will be compared between the investigational vaccine (NBP608) and a licensed varicella vaccine (Varivax®) 6 weeks after the second dose. The FAMA seroconversion rate is defined as the proportion of participants who are seronegative at baseline (antibody t
- Ratio of gpELISA Geometric Mean Titers 6 Weeks After the Second Dose(6 weeks after the second dose.) — gpELISA geometric mean titers will be compared between the investigational vaccine (NBP608) and a licensed varicella vaccine(Varivax®) 6 weeks after the second dose.
Readout outlook and evidence gap
The current protocol points to not reported as the best available readout proxy. Because this is an active or newly posted study, a trial-specific result citation is not included until a normalized clinical-trial-result record becomes available. That gap is itself operationally important: teams should monitor first result indexing, conference abstracts, protocol amendments and changes to the primary-completion date.
Build a living trial monitor:connect to PatSnap MCP Servers and track recruitment, endpoint revisions, projected readouts and new result records without manually reconciling separate databases.
Asset and sponsor context
Drug & Asset MCP profile: Herpes zoster vaccine (SK Chemicals) is indexed as No normalized modality returned, with target No normalized target returned, mechanism No normalized mechanism returned, and global highest development status No normalized global status returned.
Company & Deal Intelligence MCP profile: SK bioscience Co., Ltd. is resolved to a normalized organization record in Seongnam-si, South Korea. The organization workflow adds identity, location, portfolio and partnering context where available.
The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can determine whether a positive signal becomes a competitive asset.
White space around this program
- Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
- Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
- Comparator relevance: evidence against the most decision-relevant contemporary standard of care.
- Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
- Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.
What to monitor next
Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter the probability of success before a headline data release.
Bottom line
NCT07415252 provides a focused lens on Chickenpox development. Its value will be determined by whether Herpes zoster vaccine (SK Chemicals) can convert the current Phase 3 design into evidence that is clinically meaningful, operationally credible and differentiated from competing programs.
Ready to reproduce this analysis?Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.
